New drug ST101 takes on Hard-to-Treat cancers

NCT ID NCT04478279

Ongoing Disease control Sponsor: Sapience Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ST101 (an experimental drug given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for several hard-to-treat cancers like glioblastoma and metastatic melanoma.
What could go wrong: This is an early phase 1-2 trial with only 125 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast carcinoma breast neoplasm carcinoma castration-resistant prostate carcinoma glioblastoma glioma susceptibility 1 hormone receptor-positive breast cancer melanoma metastatic melanoma metastatic prostate carcinoma neoplasm prostate cancer sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN CANCER BREAST CANCER GBM GLIOBLASTOMA GLIOBLASTOMA MULTIFORME MELANOMA RECURRENT MELANOMA STAGE IV METASTATIC BREAST CANCER METASTATIC MELANOMA METASTATIC PROSTATE CANCER NEWLY DIAGNOSED GLIOBLASTOMA PROSTATE CANCER PROSTATE CANCER METASTATIC RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

Columbia University

New York, New York, 10032, United States
Duke University School of Medicine

Durham, North Carolina, 27708, United States
Edinburgh Cancer Centre

Edinburgh, EH4 2SP, United Kingdom
Northwestern Medicine Cancer Centers

Warrenville, Illinois, 60555, United States
START Midwest

Grand Rapids, Michigan, 49503, United States
Sarah Cannon Research Institute

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute UK

London, W1G 6AD, United Kingdom
The Beaston West of Scotland Cancer Centre

Glasgow, G12 0YN, United Kingdom
University of California, San Francisco

San Francisco, California, 94143, United States
University of Leeds

Leeds, LS9 7TF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.